CD28_NN
costimulation_NN
augments_VBZ
IL-2_NN
secretion_NN
of_IN
activated_VBN
lamina_NN
propria_NN
T_NN
cells_NNS
by_IN
increasing_VBG
mRNA_NN
stability_NN
without_IN
enhancing_VBG
IL-2_NN
gene_NN
transactivation_NN
._.

The_DT
pathways_NNS
leading_VBG
to_TO
activation_NN
in_IN
lamina_NN
propria_NN
-LRB-_-LRB-
LP_NN
-RRB-_-RRB-
T_NN
cells_NNS
are_VBP
different_JJ
from_IN
peripheral_JJ
T_NN
cells_NNS
._.

LP_NN
T_NN
cells_NNS
exhibit_VBP
enhanced_VBN
IL-2_NN
secretion_NN
when_WRB
activated_VBN
through_IN
the_DT
CD2_NN
pathway_NN
._.

Coligation_NN
of_IN
CD28_NN
leads_VBZ
to_TO
synergistic_JJ
enhancement_NN
of_IN
IL-2_NN
secretion_NN
._.

Previous_JJ
studies_NNS
have_VBP
characterized_VBN
the_DT
CD28_NN
augmentation_NN
of_IN
TCR-mediated_JJ
signaling_NN
in_IN
peripheral_JJ
blood_NN
T_NN
cells_NNS
through_IN
transcriptional_JJ
activation_NN
of_IN
an_DT
IL-2_NN
promoter_NN
CD28_NN
response_NN
element_NN
-LRB-_-LRB-
CD28RE_NN
-RRB-_-RRB-
,_,
along_IN
with_IN
enhanced_VBN
mRNA_NN
stability_NN
._.

This_DT
study_NN
characterized_VBD
molecular_JJ
events_NNS
involved_VBN
in_IN
CD28_NN
costimulation_NN
of_IN
IL-2_NN
production_NN
in_IN
LP_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
LPMC_NN
-RRB-_-RRB-
._.

LPMC_NN
exhibited_VBD
increased_VBN
IL-2_NN
production_NN
in_IN
response_NN
to_TO
CD28_NN
costimulation_NN
,_,
compared_VBN
with_IN
cells_NNS
activated_VBN
through_IN
CD2_NN
alone_RB
._.

IL-2_NN
secretion_NN
was_VBD
paralleled_VBN
by_IN
increased_VBN
expression_NN
of_IN
IL-2_NN
mRNA_NN
,_,
resulting_VBG
from_IN
enhanced_VBN
IL-2_NN
mRNA_NN
stability_NN
._.

In_IN
contrast_NN
to_TO
transcriptional_JJ
activation_NN
in_IN
PBMC_NN
,_,
EMSA_NN
revealed_VBD
that_IN
CD28_NN
coligation_NN
of_IN
CD2-activated_JJ
LPMC_NN
does_VBZ
not_RB
result_VB
in_IN
increased_VBN
binding_NN
of_IN
trans-factors_NNS
to_TO
the_DT
CD28RE_NN
,_,
nor_CC
did_VBD
Western_NN
blots_NNS
detect_VB
changes_NNS
in_IN
I-kappaBalpha_NN
or_CC
I-kappaBbeta_NN
levels_NNS
following_VBG
CD28_NN
coligation_NN
._.

Furthermore_RB
,_,
CD28_NN
coligation_NN
fails_VBZ
to_TO
enhance_VB
IL-2_NN
promoter-reporter_NN
or_CC
RE\/AP_NN
construct_NN
expression_NN
in_IN
CD2-activated_JJ
LPMC_NN
._.

The_DT
results_NNS
reported_VBN
herein_RB
indicate_VBP
that_IN
the_DT
molecular_JJ
mechanisms_NNS
involved_VBN
in_IN
CD28_NN
cosignaling_NN
and_CC
regulation_NN
of_IN
IL-2_NN
secretion_NN
in_IN
LP_NN
T_NN
cells_NNS
are_VBP
unique_JJ
to_TO
that_DT
compartment_NN
and_CC
differ_VBP
from_IN
those_DT
seen_VBN
in_IN
peripheral_JJ
blood_NN
T_NN
cells_NNS
._.

These_DT
observations_NNS
suggest_VBP
a_DT
biological_JJ
significance_NN
for_IN
different_JJ
mechanisms_NNS
of_IN
IL-2_NN
activation_NN
in_IN
initiation_NN
and_CC
maintenance_NN
of_IN
the_DT
cytokine_NN
repertoire_NN
found_VBN
in_IN
the_DT
mucosa_NN
._.

